Full-Life Technologies Reports Encouraging Preliminary Phase 1 Safety and PSA Decline for FL-020 in mCRPC at ESMO 2026

Data included dose levels of 6, 7 and 8 MBq. PSA50, PSA80 and PSA90 represent maximum PSA declines of at least 50%, 80% and 90% from baseline, respectively. No dose-limiting…

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.morningstar.com)